Kathleen Mullin1, David Kudrow2, Robert Croop2, Meghan Lovegren2, Charles M Conway2, Vladimir Coric2, Richard B Lipton2. 1. From the New England Institute of Neurology and Headache (K.M.), Stamford, CT; California Medical Clinic for Headache (D.K.), Santa Monica; Biohaven Pharmaceuticals, Inc (R.C., M.L., C.M.C., V.C.), New Haven, CT; and Albert Einstein College of Medicine (R.B.L.), Bronx, NY. kate@neinh.com. 2. From the New England Institute of Neurology and Headache (K.M.), Stamford, CT; California Medical Clinic for Headache (D.K.), Santa Monica; Biohaven Pharmaceuticals, Inc (R.C., M.L., C.M.C., V.C.), New Haven, CT; and Albert Einstein College of Medicine (R.B.L.), Bronx, NY.
Abstract
OBJECTIVE: To provide the first clinical report that 2 calcitonin gene-related peptide (CGRP) therapies, a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody, can be used concomitantly to treat refractory migraine. METHODS: Case reports are presented of 2 patients participating in a long-term safety study of rimegepant 75 mg oral tablets for acute treatment (NCT03266588). After Food and Drug Administration approval of erenumab, both patients started subcutaneous erenumab monthly as allowed per protocol. RESULTS: Patients were women 44 and 36 years of age with ≥2 decades of self-reported suboptimal response to multiple migraine medications. Patient 1 used rimegepant for 6 months and then started erenumab 70 mg subcutaneous monthly. Despite a response to preventive treatment with erenumab, she experienced substantial relief treating 7 of 7 acute attacks with rimegepant and eliminated regular, frequent use of ibuprofen and a caffeinated analgesic. Patient 2 used rimegepant for 60 days before starting erenumab 140 mg subcutaneously monthly. While on erenumab, 9 of 9 attacks treated with rimegepant responded. She stopped near-daily use of injectable ketorolac and diphenhydramine. While using rimegepant alone or together with erenumab, patients reported no adverse events. CONCLUSIONS: Rimegepant 75 mg may be effective for acute treatment during concomitant erenumab preventive administration. The mechanism underlying the benefits of concomitant use of a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody is unknown and requires further study. CLINICALTRIALSGOV IDENTIFIER: NCT03266588. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with migraine using erenumab, rimegepant is effective for acute treatment.
OBJECTIVE: To provide the first clinical report that 2 calcitonin gene-related peptide (CGRP) therapies, a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody, can be used concomitantly to treat refractory migraine. METHODS: Case reports are presented of 2 patients participating in a long-term safety study of rimegepant 75 mg oral tablets for acute treatment (NCT03266588). After Food and Drug Administration approval of erenumab, both patients started subcutaneous erenumab monthly as allowed per protocol. RESULTS:Patients were women 44 and 36 years of age with ≥2 decades of self-reported suboptimal response to multiple migraine medications. Patient 1 used rimegepant for 6 months and then started erenumab 70 mg subcutaneous monthly. Despite a response to preventive treatment with erenumab, she experienced substantial relief treating 7 of 7 acute attacks with rimegepant and eliminated regular, frequent use of ibuprofen and a caffeinated analgesic. Patient 2 used rimegepant for 60 days before starting erenumab 140 mg subcutaneously monthly. While on erenumab, 9 of 9 attacks treated with rimegepant responded. She stopped near-daily use of injectable ketorolac and diphenhydramine. While using rimegepant alone or together with erenumab, patients reported no adverse events. CONCLUSIONS:Rimegepant 75 mg may be effective for acute treatment during concomitant erenumab preventive administration. The mechanism underlying the benefits of concomitant use of a small molecule CGRP receptor antagonist and an anti-CGRP receptor antibody is unknown and requires further study. CLINICALTRIALSGOV IDENTIFIER: NCT03266588. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with migraine using erenumab, rimegepant is effective for acute treatment.
Authors: Amnon A Berger; Ariel Winnick; Austin H Carroll; Alexandra Welschmeyer; Nathan Li; Marc Colon; Antonella Paladini; Giovanni F Ramírez; Jamal Hasoon; Elyse M Cornett; Jaehong Song; Giustino Varrassi; Adam M Kaye; Alan D Kaye; Latha Ganti Journal: Health Psychol Res Date: 2022-10-12
Authors: Abhijeet Jakate; Andrew M Blumenfeld; Ramesh Boinpally; Matthew Butler; Lisa Borbridge; Janette Contreras-De Lama; Danielle McGeeney; Antonia Periclou; Richard B Lipton Journal: Headache Date: 2021-04-05 Impact factor: 5.887
Authors: Rabia Latif; Nazish Rafique; Lubna Al Asoom; Ahmed A Alsunni; Ayad Mohammed Salem; Dinah Abdulhadi AlNoaimi; Wasan Mohammed AlHarbi; Ahad Yasir Shaikh; Shoug Abdullah AlRaddadi; Leena Abdulrahman AlMuhaish; Dana Almohazey; Sayed Abdulazeez; J Francis Borgio Journal: Int J Gen Med Date: 2021-03-12
Authors: Gary Berman; Robert Croop; David Kudrow; Philip Halverson; Meghan Lovegren; Alexandra C Thiry; Charles M Conway; Vladimir Coric; Richard B Lipton Journal: Headache Date: 2020-08-16 Impact factor: 5.887
Authors: Francesco De Logu; Romina Nassini; Alan Hegron; Lorenzo Landini; Dane D Jensen; Rocco Latorre; Julia Ding; Matilde Marini; Daniel Souza Monteiro de Araujo; Paulina Ramírez-Garcia; Michael Whittaker; Jeffri Retamal; Mustafa Titiz; Alessandro Innocenti; Thomas P Davis; Nicholas Veldhuis; Brian L Schmidt; Nigel W Bunnett; Pierangelo Geppetti Journal: Nat Commun Date: 2022-02-03 Impact factor: 17.694